Home › Glioblastoma › Pennsylvania
Glioblastoma clinical trials in Pennsylvania
21 studies for Glioblastoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05432804A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT03970447Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- Penn State Health Milton S. Hershey Medical Center, Hershey
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05902169Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07326566A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- Allegheny Health Network, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07195591Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
- Hospital of the University of Pennsylvania, Philadelphia
- University of Pennsylvania, Philadelphia
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06613841Targeted Pediatric High-Grade Glioma Therapy
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT02977780WBSI Guided Personalized Delivery of TTFields
- Abramson Cancer Center, Philadelphia
- Penn Medicine, University of Pennsylvania, Philadelphia
Recruiting
Ages 22 and older · All sexes · Updated Aug 6, 2026 · NCT05086497Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
- Penn State Milton S. Hershey Medical Center, Hershey
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jul 17, 2026 · NCT07225621DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- UPMC Presbyterian Hospital, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Children's Hospital of Philadelphia, Philadelphia
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Jun 11, 2026 · NCT04732065Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- University of Pittsburg Medical Center (UPCM), Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05283330Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Philadelphia
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Penn State Milton S. Hershey Medical Center, Hershey
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 27, 2025 · NCT03175224From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.